As a result of improved effectiveness of first-, second-line and maintenance therapeutic
regimens in non-small cell lung cancer, there is need for new options as third-line treatment …

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance
due to individual tailoring of the therapeutic options and the use of strategies based on both …

Objectives This study was conducted to evaluate the efficacy and safety of apatinib in
advanced NSCLC patients with EGFR wild-type who have failed more than second-line …

Aim: To evaluate the cost utility and budget impact of second‐line gefitinib for non‐small cell
lung cancer from a Thai payer perspective. Methods: A Markov model with three health …

Background: The pretreatment of dexamethasone on the efficacy and immune-related
adverse events of immunotherapy involving programmed cell death 1/programmed cell …

Aim: Cytotoxic chemotherapy is the standard first-line therapy for patients with advanced non-
small cell lung cancer (NSCLC) without specific gene alterations. This study examined the …

背景与目的培美曲赛和表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor
receptortyrosine kinase inhibitors, EGFR-TKIs) 对于有EGFR 基因突变的非小细胞肺癌(non …

Objective: To explore the effect of Kanglaite injection combined with chemotherapy on the
levels of tumor factors, angiogenesis and immunoglobulin in patients with lung …

Rak płuca dzieli się na dwie główne grupy, zależnie od typu histologicznego: rak
drobnokomórkowy (SCLC) i niedrobnokomórkowy (NSCLC). Mimo że podstawową metodą …

Abstract Abstract Background and objective Pemetrexed and epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) were used in patients with EGFR mutation …